Company profile
XOMA Royalty Corporation logo

XOMA Royalty Corporation

Pipeline18 assets

  • Vabysmofaricimab-svoa / VABYSMO / VEGF/Ang-2 / Bispecific antibody / Ophthalmology
    Neovascular age-related macular degeneration (nAMD) and Diabetic macular edema (DME)Approvedapproved
  • Ojemdatovorafenib / OJEMDA / Oncology
    Oncology (undisclosed approved indication)Approvedapproved
  • Miplyffaarimoclomol / MIPLYFFA / Rare Diseases / Neurology
    Niemann-Pick disease type C (NPC)ApprovedapprovedUS
  • Xaciatoclindamycin phosphate vaginal gel 2% / XACIATO / Small molecule / Gynecology / Infectious Disease
    Bacterial VaginosisApprovedapproved
  • Ixinitycoagulation factor IX (recombinant) / IXINITY / Factor IX / Recombinant protein / Hematology
    Hemophilia BApprovedapproved
  • Dsuviasufentanil sublingual tablet / DSUVIA / Opioid receptor / Small molecule / Pain Management
    PainApprovedapproved
  • Dare to Playsildenafil cream / DARE to PLAY / PDE5 / Small molecule / Gynecology / Sexual Health
    Female Sexual Arousal DisorderApprovedapproved
  • ersodetugRZ358 / INSR / Antibody / Metabolic Disorders
    Hypoglycemia due to congenital hyperinsulinism (cHI)Phase 3ongoingHypoglycemia due to tumor hyperinsulinismPhase 3ongoing
  • RZ402RZ402 / Ophthalmology
    Diabetic macular edema (DME)Phase 2ongoing
  • D-FiFCX-007 / Gene Therapy / Dermatology / Rare Diseases
    Dystrophic epidermolysis bullosa (DEB)Phase 3ongoing
  • seralutinibGB002 / PDGFR, CSF1R, and c-KIT / Inhaled tyrosine kinase inhibitor / Respiratory / Cardiovascular
    Pulmonary arterial hypertension (PAH)Phase 3ongoingPulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Phase 2ongoing
  • cetrelimabJNJ-63723283 / PD-1 / Antibody / Oncology / Infectious Disease
    Muscle-invasive bladder cancer (MIBC)Phase 2ongoingChronic Hepatitis B Virus InfectionPhase 2ongoing
  • volixibatLUM-002 / Ileal bile acid transporter (IBAT) / Small molecule / Gastroenterology
    Primary sclerosing cholangitis (PSC)Phase 2bongoingPrimary biliary cholangitis (PBC)Phase 2ongoing
  • osavampatorNeurology / Psychiatry
    Major depressive disorderPhase 3ongoing
  • OHB-607OHB-607 / Recombinant human IGF-I/IGFBP-3 / Recombinant protein / Respiratory / Neonatology
    Prevention of bronchopulmonary dysplasia in extremely premature infantsPhase 2ongoing
  • REC-4881REC-4881 / Allosteric MEK1/2 / Small molecule / Oncology
    Familial adenomatous polyposisPhase 2ongoing
  • NIS793NIS793 / Antibody / Oncology
    Solid tumorsPhase 3ongoing
  • QTORIN rapamycinQTORIN / mTOR / Small molecule / Dermatology / Rare Diseases
    Cutaneous venous malformationsPhase 3ongoingClinically significant angiokeratomasPhase 2ongoing

Latest news10 items

All news

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator

Transaction expands Ligand’s royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand’s long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient access and improve lives Acquisition is expected to be immediately...

XOMA Royalty Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq:...

XOMA Royalty to Present at Investor Conferences in March

EMERYVILLE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following investor conferences in March. Management will also participate in one-on-one investor meetings. T.D....

XOMA Royalty Announces CFO Transition

EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from his position with XOMA Royalty to pursue other professional opportunities....

XOMA Royalty Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulative Preferred Stock:...

XOMA Royalty Enters into Agreement to Acquire Generation Bio

- Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna - - Generation Bio’s cell-targeted lipid nanoparticles (ctLNP) delivery platform for small interfering RNA (siRNA) and other nucleic acid therapies to be included in XOMA Royalty’s portfolio - EMERYVILLE, Calif....